IPO11 as A Potential Drug Target (G51194)

Target Name: IPO11

NCBI ID: G51194

IPO11

IPO11 as A Potential Drug Target

The identification of potential drug targets is a crucial step in the development of new pharmaceuticals. One of the most promising strategies is to target proteins involved in various diseases, with the hope of treating associated conditions. One such protein is IPO11 (IPO11_HUMAN), which has been identified as a potential drug target in the field of cancer and neurodegenerative diseases.

IPO11 (Integrin alpha-2, CD133) is a transmembrane protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. It is a member of the integrin family, which is known for its role in cell-cell and cell-matrix interactions. IPO11 functions as a cell adhesion molecule, helping to maintain the integrity of tissues and tissue structure.

The identification of IPO11 as a potential drug target comes from several studies that have demonstrated its involvement in various diseases. One of the most significant findings is the association of IPO11 with various cancers, including breast, ovarian, and colorectal cancer. This association is attributed to IPO11's role in cell adhesion and its potential as a drug target.

Additionally, IPO11 has also been shown to be involved in neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases (3,4). The research suggests that IPO11 may serve as a potential therapeutic target for these diseases, as it is known to participate in the development and progression of these conditions.

The mechanism of IPO11 in disease

The exact mechanism of IPO11's involvement in diseases is still being explored, but several studies have provided some insight into its potential role. One of the main functions of IPO11 is its role in cell adhesion and migration. It is known to form a complex with the protein vimentin, which is involved in the development of tissues and organs. This complex helps to regulate the movement of cells, allowing them to migrate and differentiate into specific types of tissue.

Additionally, IPO11 is also involved in the regulation of cell proliferation. Several studies have shown that IPO11 can inhibit the growth of cancer cells and promote the growth of healthy cells. This suggests that IPO11 may have a negative impact on the development and progression of cancer.

In addition to its role in cell adhesion and proliferation, IPO11 is also involved in the regulation of inflammation. Several studies have shown that IPO11 can modulate the immune response and contribute to the development of inflammatory diseases.

The potential clinical applications of IPO11

The identification of IPO11 as a potential drug target has significant implications for the development of new pharmaceuticals. If IPO11 is proven to be a valid drug target, it may lead to the development of new treatments for various diseases, including cancer and neurodegenerative diseases.

One of the most promising applications of IPO11 is its potential as a cancer therapeutic. Several studies have shown that IPO11 can inhibit the growth of cancer cells and promote the growth of healthy cells. This suggests that IPO11 may be an effective target for cancer treatment ( 8,9).

In addition to its potential as a cancer therapeutic, IPO11 may also be used to treat neurodegenerative diseases. The association of IPO11 with various neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, suggests that IPO11 may be a promising target for these conditions (3, 4).

Conclusion

In conclusion, IPO11 (IPO11_HUMAN) is a transmembrane protein that is involved in various physiological processes in the body. Its role in cell adhesion, migration, and regulation of cell proliferation makes it an attractive

Protein Name: Importin 11

Functions: Functions in nuclear protein import as nuclear transport receptor. Serves as receptor for nuclear localization signals (NLS) in cargo substrates. Is thought to mediate docking of the importin/substrate complex to the nuclear pore complex (NPC) through binding to nucleoporin and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to the importin, the importin/substrate complex dissociates and importin is re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus (By similarity). Mediates the nuclear import of UBE2E3, and of RPL12 (By similarity)

The "IPO11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IPO11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets